An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors

By sjmartinez • June 23, 2023

Nadres B, Momcilovic M, Shackelford DB, Lisberg A. An Unexpected Partnership: Histone Deacetylase 6 and Glutaminase Inhibition Provide an Opportunity to Overcome Resistance in KRAS and LKB1 Co-mutant Lung Tumors. J Thorac Oncol. 2023 Jul;18(7):847-850. doi: 10.1016/j.jtho.2023.04.012. PMID: 37348993.

Tags: Hematology/Oncology, Publications, Pulmonary, Critical Care & Sleep Medicine

Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials

Zhao S, Cheng Y, Wang Q, Li X, Liao J, Rodon J, Meng X, Luo Y, Chen Z, Wang W, Yi T, Li Y, Yin[...]

Body mass index as a predictive factor for efficacy of adjuvant taxane-based chemotherapy in early-stage breast cancer patients: A pooled analysis from adjuvant GEICAM Spanish Breast Cancer Group and TRIO Translational Research in Oncology Group studies

García-Saenz JA, Spera G, Pollán M, Bermejo B, Ruiz-Borrego M, Chan A, Martín M, Guerrero-Zotano Á, Calvo L, Rodríguez-Lescure Á, Marín M, Chap L, Crown[...]

Omidubicel-onlv Transplantation for Hematologic Malignancies: Results of a Multicenter Expanded Access Program

Horwitz ME, Schiller GJ, Tsai SB, Rezvani AR, Maziarz RT, Goshen U, Levy S, Schwarzbach A, Mazor RD, Stiff PJ. Omidubicel-onlv Transplantation for Hematologic Malignancies:[...]